These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36819192)

  • 1. Antibody-removal therapies for de novo DSA in pediatric intestinal recipients: Why, when, and how? A single-center experience.
    Lasa-Lázaro M; Ramos-Boluda E; Mancebo E; Castro-Panete MJ; González-Sacristán R; Serradilla J; Andrés-Moreno AM; Hernández-Oliveros F; Paz-Artal E; Talayero P
    Front Pediatr; 2022; 10():1074577. PubMed ID: 36819192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
    Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor-Specific Antibodies in Pediatric Intestinal and Multivisceral Transplantation: The Role of Liver and Human Leukocyte Antigen Mismatching.
    Talayero P; Ramos Boluda E; Gómez Massa E; Castro Panete MJ; Prieto Bozano G; Hernández Oliveros F; López Santamaría M; Calvo Pulido J; Paz-Artal E; Mancebo E
    Liver Transpl; 2018 Dec; 24(12):1726-1735. PubMed ID: 30112820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
    Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
    J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical impact of donor-specific antibodies in heart transplantation.
    Barten MJ; Schulz U; Beiras-Fernandez A; Berchtold-Herz M; Boeken U; Garbade J; Hirt S; Richter M; Ruhpawar A; Sandhaus T; Schmitto JD; Schönrath F; Schramm R; Schweiger M; Wilhelm M; Zuckermann A
    Transplant Rev (Orlando); 2018 Oct; 32(4):207-217. PubMed ID: 29804793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.
    Tikkanen JM; Singer LG; Kim SJ; Li Y; Binnie M; Chaparro C; Chow CW; Martinu T; Azad S; Keshavjee S; Tinckam K
    Am J Respir Crit Care Med; 2016 Sep; 194(5):596-606. PubMed ID: 26967790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury.
    Yamamoto T; Watarai Y; Takeda A; Tsujita M; Hiramitsu T; Goto N; Narumi S; Katayama A; Morozumi K; Uchida K; Kobayashi T
    Transplantation; 2016 Oct; 100(10):2194-202. PubMed ID: 26636737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Donor-Specific Antibodies in Intestinal Transplantation: Experience at the University of California Los Angeles and Literature Review.
    Cheng EY; Kaneku H; Farmer DG
    Clin Transpl; 2014; ():153-9. PubMed ID: 26281140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant.
    Tagliamacco A; Cioni M; Comoli P; Ramondetta M; Brambilla C; Trivelli A; Magnasco A; Biticchi R; Fontana I; Dulbecco P; Palombo D; Klersy C; Ghiggeri GM; Ginevri F; Cardillo M; Nocera A
    Transpl Int; 2014 Jul; 27(7):667-73. PubMed ID: 24629017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies.
    Parajuli S; Aziz F; Blazel J; Muth BL; Garg N; Mohamed M; Rice J; Mezrich JD; Hidalgo LG; Mandelbrot D
    Transplantation; 2021 Jul; 105(7):1548-1555. PubMed ID: 32732618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.
    Cheng EY; Everly MJ; Kaneku H; Banuelos N; Wozniak LJ; Venick RS; Marcus EA; McDiarmid SV; Busuttil RW; Terasaki PI; Farmer DG
    Transplantation; 2017 Apr; 101(4):873-882. PubMed ID: 27490417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Monitoring of Donor-specific Anti-HLA Antibodies After Intestine/Multivisceral Transplantation: Significance of De Novo Antibodies.
    Kubal C; Mangus R; Saxena R; Lobashevsky A; Higgins N; Fridell J; Tector AJ
    Transplantation; 2015 Aug; 99(8):e49-56. PubMed ID: 25769071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
    Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
    Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of
    Zhu L; Guo Z; Zhao D; Sa R; Zhao G; Guo H; Chen G
    Front Immunol; 2022; 13():1087597. PubMed ID: 36713391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo donor-specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA?
    Moayedi Y; Fan CS; Tinckam KJ; Ross HJ; McCaughan JA
    Clin Transplant; 2018 Nov; 32(11):e13416. PubMed ID: 30276870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients.
    Lee H; Min JW; Kim JI; Moon IS; Park KH; Yang CW; Chung BH; Oh EJ
    Medicine (Baltimore); 2016 Mar; 95(11):e3094. PubMed ID: 26986147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of de novo donor-specific antibody in kidney transplant recipients with chronic antibody-mediated rejection.
    Park WY; Kim Y; Paek JH; Jin K; Han S
    Korean J Transplant; 2021 Mar; 35(1):33-40. PubMed ID: 35769616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of de novo donor-specific antibody on early renal allograft function recovery.
    Zheng J; Xue W; Jing X; Hou J; Tian X; Tian P; Ding X; Pan X; Yan H; Feng X; Xiang H; Li Y; Ding C
    Ren Fail; 2015 Apr; 37(3):462-8. PubMed ID: 25697229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.